Error loading player: No playable sources found

ICH Q5A(R2)

Date
July 14, 2021
This product is not available for individual purchase, but it is available as part of the following products:

Since the publication of the Q5A(R1) Guideline in 1999, there has been advances in biotechnology product development and manufacturing that are not reflected in the original guideline. Additionally, emergence of new virus detection technologies and evolvement of strategies for virus clearance strategies based on manufacturing experience and scientific consensus has occurred. The revision of ICH Q5A(R2) was endorsed as a new topic for ICH harmonization in June 2019 and the concept paper was published in Nov 2019. The following areas were proposed for updating the ICH Q5A(R1):

• New classes of biotechnology products (e.g., virus-like particles (VLPs), subunit proteins, and viral-vectored products)
• Additional validation approaches for virus clearance (e.g., modular validation)
• New virus assays and alternative analytical methods (e.g., PCR, NGS)
• Virus clearance validation and risk mitigation strategies for advanced manufacturing (e.g., continuous manufacturing)
• Aspects of virus clearance validation that have emerged or evolved

This session will include brief presentations to describe the context for revisions to the guideline, and then provide opportunity for discussions related to their incorporation. For example:
1. How will the updates support or impact your current manufacturing process and practices?
2. Do you think the updates will address current gaps? Do you have additional suggestions within the scope of the updates?
3. What are the most challenging topics within viral safety validation for continuous / advanced manufacturing?

Session Chairs

Speaker Image for Arifa Khan
CBER, FDA
Speaker Image for Joel Welch
CDER, FDA

Session Speakers

Speaker Image for Marie Murphy
Eli Lilly Kinsale Limited
Speaker Image for Dominick Vacante
Janssen Pharmaceutical R&D, LLC

Related Products

Thumbnail for Panel Discussions and Closing Remarks
Panel Discussions and Closing Remarks
Join Roundtables & ICH Quality Guidelines Panel Discussion [https://live.remo…
Thumbnail for Revision of ICH Q2(R1) and the New Guidance
Revision of ICH Q2(R1) and the New Guidance
Efforts are underway to update and expand the applicability of ICH Q2(R1), Validation of Analytical Procedures, the authoritative guidance on analytical method validation…
Thumbnail for ICH Q13: Continuous Manufacturing Guidance
ICH Q13: Continuous Manufacturing Guidance
ICH Q13, Continuous Manufacturing of Drug Substances and Drug Products, is progressing through document development with endorsement of Stage 1 expected in May 2021…